FDA Fully Approves Selpercatinib for RET Gene Fusion Cancers

The U.S. FDA has granted full approval to selpercatinib (Retevmo) for treating advanced cancers in patients aged two and older who possess a rare RET gene fusion. This targeted therapy works by deactivating the RET gene fusion, effectively halting cell growth across various tumor types, including lung, thyroid, pancreatic, ovarian, and certain pediatric cancers. This approval expands treatment options for a specific group of cancer patients.